|
2020-12-11 |
2020-12-09 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
97 208
+33.3%
214,04
4.274.137 US$
|
97 208
+33.3%
|
214,04
|
4.274.137 US$
|
|
|
2020-11-17 |
2020-11-16 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
95 249
+14.7%
241,78
3.423.540 US$
|
95 249
+14.7%
|
241,78
|
3.423.540 US$
|
|
|
2020-11-17 |
2020-11-13 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
75 667
+25.1%
415,68
3.152.651 US$
|
75 667
+25.1%
|
415,68
|
3.152.651 US$
|
|
|
2020-11-12 |
2020-11-10 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
6 000
-51.6%
81,57
489.420 US$
|
6 000
-51.6%
|
81,57
|
489.420 US$
|
|
|
2020-11-06 |
2020-11-05 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
3 589
-39.0%
79,87
286.653 US$
|
3 589
-39.0%
|
79,87
|
286.653 US$
|
|
|
2020-11-06 |
2020-11-04 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
3 434
-37.9%
79,89
274.351 US$
|
3 434
-37.9%
|
79,89
|
274.351 US$
|
|
|
2020-11-06 |
2020-11-04 |
S
Venta
|
SVP & Controller
Oficial
|
139
-0.6%
80,00
11.120 US$
|
139
-0.6%
|
80,00
|
11.120 US$
|
|
|
2020-11-06 |
2020-11-04 |
S
Venta
|
SVP & Controller
Oficial
|
2 481
-9.7%
80,00
198.481 US$
|
2 481
-9.7%
|
80,00
|
198.481 US$
|
|
|
2020-10-20 |
2020-10-16 |
S
Venta
|
CEO, Magellan Rx Management
Oficial
|
183
-3.2%
79,87
14.616 US$
|
183
-3.2%
|
79,87
|
14.616 US$
|
|
|
2020-10-07 |
2020-10-07 |
S
Venta
|
SVP & Controller
Oficial
|
1 500
-6.1%
78,50
117.753 US$
|
1 500
-6.1%
|
78,50
|
117.753 US$
|
|
|
2020-10-07 |
2020-10-06 |
S
Venta
|
SVP & Controller
Oficial
|
4 778
-17.2%
78,50
375.094 US$
|
4 778
-17.2%
|
78,50
|
375.094 US$
|
|
|
2020-10-07 |
2020-10-05 |
S
Venta
|
SVP & Controller
Oficial
|
14 637
-38.9%
78,51
1.149.110 US$
|
14 637
-38.9%
|
78,51
|
1.149.110 US$
|
|
|
2020-06-10 |
2020-06-08 |
S
Venta
|
SVP & Controller
Oficial
|
1 415
-5.8%
78,50
111.078 US$
|
1 415
-5.8%
|
78,50
|
111.078 US$
|
|
|
2020-05-19 |
2020-05-15 |
B
Compra
|
President and COO
Oficial
|
4 500
+inf%
67,63
304.317 US$
|
4 500
+inf%
|
67,63
|
304.317 US$
|
|
|
2020-01-03 |
2020-01-02 |
S
Venta
|
SVP & Controller
|
200
-1.0%
78,53
15.706 US$
|
200
-1.0%
|
78,53
|
15.706 US$
|
|
|
2019-12-31 |
2019-12-30 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
104
-0.5%
78,50
8.164 US$
|
104
-0.5%
|
78,50
|
8.164 US$
|
|
|
2019-12-30 |
2019-12-27 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
606
-2.9%
78,54
47.597 US$
|
606
-2.9%
|
78,54
|
47.597 US$
|
|
|
2019-12-27 |
2019-12-26 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
1 923
-8.7%
78,52
150.987 US$
|
1 923
-8.7%
|
78,52
|
150.987 US$
|
|
|
2019-12-26 |
2019-12-24 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
6 114
-23.3%
78,54
480.166 US$
|
6 114
-23.3%
|
78,54
|
480.166 US$
|
|
|
2019-12-17 |
2019-12-16 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
5 735
-22.1%
78,62
450.886 US$
|
5 735
-22.1%
|
78,62
|
450.886 US$
|
|
|
2019-12-11 |
2019-12-09 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
Oficial
|
16 766
-85.7%
78,72
1.319.742 US$
|
16 766
-85.7%
|
78,72
|
1.319.742 US$
|
|
|
2018-07-03 |
2018-07-02 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 375
-30.5%
95,86
1.282.061 US$
|
13 375
-30.5%
|
95,86
|
1.282.061 US$
|
|
|
2018-06-04 |
2018-06-01 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 375
-30.5%
92,21
1.233.326 US$
|
13 375
-30.5%
|
92,21
|
1.233.326 US$
|
|
|
2018-05-02 |
2018-05-01 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 375
-23.2%
86,02
1.150.576 US$
|
13 375
-23.2%
|
86,02
|
1.150.576 US$
|
|
|
2018-04-04 |
2018-04-02 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
Oficial
|
1 666
-100.0%
106,20
176.929 US$
|
1 666
-100.0%
|
106,20
|
176.929 US$
|
|
|
2018-04-04 |
2018-04-02 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 375
-23.2%
103,52
1.384.583 US$
|
13 375
-23.2%
|
103,52
|
1.384.583 US$
|
|
|
2018-03-06 |
2018-03-05 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
15 428
-100.0%
99,04
1.527.968 US$
|
15 428
-100.0%
|
99,04
|
1.527.968 US$
|
|
|
2018-03-06 |
2018-03-05 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
22 875
-63.0%
99,05
2.265.698 US$
|
22 875
-63.0%
|
99,05
|
2.265.698 US$
|
|
|
2018-03-02 |
2018-03-01 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 375
-31.2%
101,20
1.353.496 US$
|
13 375
-31.2%
|
101,20
|
1.353.496 US$
|
|
|
2018-02-02 |
2018-02-01 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 375
-31.2%
99,20
1.326.765 US$
|
13 375
-31.2%
|
99,20
|
1.326.765 US$
|
|
|
2018-01-04 |
2018-01-03 |
S
Venta
|
Rubin Jonathan N
Chief Financial Officer
Oficial
|
30 086
-53.2%
96,16
2.893.028 US$
|
30 086
-53.2%
|
96,16
|
2.893.028 US$
|
|
|
2018-01-03 |
2018-01-02 |
S
Venta
|
SMITH BARRY M
Chief Executive Officer
Consejero ejecutivo
|
13 367
-31.2%
95,94
1.282.429 US$
|
13 367
-31.2%
|
95,94
|
1.282.429 US$
|
|
|
2018-01-03 |
2018-01-02 |
S
Venta
|
Rubin Jonathan N
Chief Financial Officer
Oficial
|
17 443
-39.7%
96,07
1.675.782 US$
|
17 443
-39.7%
|
96,07
|
1.675.782 US$
|
|
|
2017-12-06 |
2017-12-04 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
2 180
-100.0%
92,00
200.560 US$
|
2 180
-100.0%
|
92,00
|
200.560 US$
|
|
|
2017-12-05 |
2017-12-04 |
S
Venta
|
Lewis Clapper Caskie
Chief Human Resources Officer
|
59 313
-76.3%
93,99
5.574.586 US$
|
59 313
-76.3%
|
93,99
|
5.574.586 US$
|
|
|
2017-12-04 |
2017-12-01 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
8 275
-38.1%
89,08
737.137 US$
|
8 275
-38.1%
|
89,08
|
737.137 US$
|
|
|
2017-11-02 |
2017-11-01 |
Por favor
Venta prevista
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
9 369
-41.0%
89,20
835.751 US$
|
9 369
-41.0%
|
89,20
|
835.751 US$
|
|
|
2017-11-02 |
2017-11-01 |
Por favor
Venta prevista
|
Kamal Mostafa
CEO, Magellan Rx Management
|
1 154
-100.0%
92,00
106.168 US$
|
1 154
-100.0%
|
92,00
|
106.168 US$
|
|
|
2017-10-05 |
2017-10-04 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
2 475
-15.5%
88,10
218.048 US$
|
2 475
-15.5%
|
88,10
|
218.048 US$
|
|
|
2017-10-05 |
2017-10-04 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
5 000
-23.9%
88,00
440.000 US$
|
5 000
-23.9%
|
88,00
|
440.000 US$
|
|
|
2017-10-05 |
2017-10-03 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
5 000
-27.1%
88,00
440.000 US$
|
5 000
-27.1%
|
88,00
|
440.000 US$
|
|
|
2017-10-04 |
2017-10-03 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
|
30 021
-68.3%
87,31
2.621.242 US$
|
30 021
-68.3%
|
87,31
|
2.621.242 US$
|
|
|
2017-10-03 |
2017-10-02 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
|
19 007
-57.7%
86,22
1.638.689 US$
|
19 007
-57.7%
|
86,22
|
1.638.689 US$
|
|
|
2017-10-03 |
2017-09-29 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
|
18 511
-57.1%
86,18
1.595.317 US$
|
18 511
-57.1%
|
86,18
|
1.595.317 US$
|
|
|
2017-09-29 |
2017-09-28 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
4 848
-100.0%
85,76
415.782 US$
|
4 848
-100.0%
|
85,76
|
415.782 US$
|
|
|
2017-09-29 |
2017-09-28 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
|
25 316
-64.5%
85,85
2.173.452 US$
|
25 316
-64.5%
|
85,85
|
2.173.452 US$
|
|
|
2017-09-29 |
2017-09-27 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
|
1 419
-9.2%
86,06
122.125 US$
|
1 419
-9.2%
|
86,06
|
122.125 US$
|
|
|
2017-09-29 |
2017-09-27 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
|
18 502
-54.7%
85,24
1.577.131 US$
|
18 502
-54.7%
|
85,24
|
1.577.131 US$
|
|
|
2017-09-28 |
2017-09-27 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
35 658
-72.6%
85,17
3.036.928 US$
|
35 658
-72.6%
|
85,17
|
3.036.928 US$
|
|
|
2017-09-28 |
2017-09-27 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
600
-100.0%
86,06
51.635 US$
|
600
-100.0%
|
86,06
|
51.635 US$
|
|
|
2017-09-28 |
2017-09-27 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
18 526
-96.9%
85,31
1.580.373 US$
|
18 526
-96.9%
|
85,31
|
1.580.373 US$
|
|
|
2017-09-18 |
2017-09-15 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
2 402
-15.1%
83,00
199.366 US$
|
2 402
-15.1%
|
83,00
|
199.366 US$
|
|
|
2017-09-18 |
2017-09-15 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
2 961
-100.0%
84,00
248.724 US$
|
2 961
-100.0%
|
84,00
|
248.724 US$
|
|
|
2017-09-18 |
2017-09-14 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
18 063
-57.3%
83,05
1.500.163 US$
|
18 063
-57.3%
|
83,05
|
1.500.163 US$
|
|
|
2017-09-14 |
2017-09-13 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
585
-100.0%
83,00
48.555 US$
|
585
-100.0%
|
83,00
|
48.555 US$
|
|
|
2017-09-14 |
2017-09-13 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
14 096
-51.2%
83,06
1.170.883 US$
|
14 096
-51.2%
|
83,06
|
1.170.883 US$
|
|
|
2017-09-14 |
2017-09-12 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
19
-100.0%
83,00
1.577 US$
|
19
-100.0%
|
83,00
|
1.577 US$
|
|
|
2017-09-12 |
2017-09-11 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
670
-100.0%
83,00
55.610 US$
|
670
-100.0%
|
83,00
|
55.610 US$
|
|
|
2017-09-12 |
2017-09-11 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
|
2 400
-15.1%
83,00
199.200 US$
|
2 400
-15.1%
|
83,00
|
199.200 US$
|
|
|
2017-09-11 |
2017-09-08 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
6 267
-100.0%
81,53
510.918 US$
|
6 267
-100.0%
|
81,53
|
510.918 US$
|
|
|
2017-09-08 |
2017-09-07 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
1 033
-100.0%
81,19
83.870 US$
|
1 033
-100.0%
|
81,19
|
83.870 US$
|
|
|
2017-09-08 |
2017-09-05 |
S
Venta
|
Kamal Mostafa
CEO, Magellan Rx Management
|
1 157
-100.0%
80,96
93.669 US$
|
1 157
-100.0%
|
80,96
|
93.669 US$
|
|
|
2017-07-26 |
2017-07-25 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
4 559
-25.3%
80,68
367.820 US$
|
4 559
-25.3%
|
80,68
|
367.820 US$
|
|
|
2017-07-25 |
2017-07-24 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
32 398
-70.7%
80,12
2.595.582 US$
|
32 398
-70.7%
|
80,12
|
2.595.582 US$
|
|
|
2017-07-25 |
2017-07-21 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
1 176
-8.0%
80,02
94.102 US$
|
1 176
-8.0%
|
80,02
|
94.102 US$
|
|
|
2017-07-21 |
2017-07-20 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
16 073
-54.4%
80,06
1.286.751 US$
|
16 073
-54.4%
|
80,06
|
1.286.751 US$
|
|
|
2017-07-21 |
2017-07-20 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
1 109
-7.4%
80,01
88.728 US$
|
1 109
-7.4%
|
80,01
|
88.728 US$
|
|
|
2017-07-18 |
2017-07-17 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
600
-4.1%
80,10
48.060 US$
|
600
-4.1%
|
80,10
|
48.060 US$
|
|
|
2017-07-18 |
2017-07-14 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
27 914
-66.7%
80,07
2.234.940 US$
|
27 914
-66.7%
|
80,07
|
2.234.940 US$
|
|
|
2017-07-17 |
2017-07-14 |
S
Venta
|
GREGOIRE DANIEL N
General Counsel and Secretary
Oficial
|
14 114
-51.2%
80,11
1.130.685 US$
|
14 114
-51.2%
|
80,11
|
1.130.685 US$
|
|
|
2017-02-27 |
2017-02-24 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
100
-0.9%
82,10
8.210 US$
|
100
-0.9%
|
82,10
|
8.210 US$
|
|
|
2017-02-27 |
2017-02-24 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
100
-0.9%
81,05
8.105 US$
|
100
-0.9%
|
81,05
|
8.105 US$
|
|
|
2017-02-27 |
2017-02-24 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
100
-0.9%
80,00
8.000 US$
|
100
-0.9%
|
80,00
|
8.000 US$
|
|
|
2017-02-27 |
2017-02-23 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
300
-2.5%
81,12
24.335 US$
|
300
-2.5%
|
81,12
|
24.335 US$
|
|
|
2017-02-27 |
2017-02-23 |
S
Venta
|
WEST JEFFREY N
SVP & Controller
Oficial
|
12 912
-51.9%
80,28
1.036.516 US$
|
12 912
-51.9%
|
80,28
|
1.036.516 US$
|
|